Trial Profile
A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subjects 2-17 Years of Age
Status:
Suspended
Phase of Trial:
Phase IV
Latest Information Update: 19 Jul 2023
Price :
$35
*
At a glance
- Drugs MEDI 3250 (Primary) ; Influenza virus vaccine
- Indications Influenza virus infections
- Focus Therapeutic Use
- Acronyms ICICLE
- Sponsors MedImmune
- 17 Jul 2023 Planned End Date changed from 30 Mar 2023 to 23 May 2025.
- 17 Jul 2023 Planned primary completion date changed from 30 Mar 2023 to 23 May 2025.
- 20 Apr 2020 Planned End Date changed from 30 Mar 2020 to 30 Mar 2023.